Skip to main content

Hitting the Bull’s-eye With Psoriasis Treatment

Hitting the Bull’s-eye With Psoriasis Treatment

Wed, 08/02/2017 - 19:45

Imagine a goal that once seemed out of reach—say, running a mile in under 4 minutes.

"At first it didn’t seem possible,” said April Armstrong, MD, a dermatologist at the University of Southern California, and member of the National Psoriasis Foundation (NPF) Medical Board. “But then someone did it. And now people do it all the time.”

No longer deemed unattainable, today many runners regularly clock 4-minute miles. Now NPF’s Medical Board has set a goal for psoriasis treatment that it hopes will become the new standard of care. The goal was published in a recent article in the Journal of the American Academy of Dermatology.1

Also known as a treatment target,the goal is to reduce the severity of psoriasis so it only covers 1% or less of the body. It is a target that may seem tough to achieve—just like the 4-minute mile once did. But with the growing number of treatments available and increased understanding of the disease, the goal could soon be achieved by everyone with psoriasis.

Treatments, Targets, and Timing

People with psoriasis and dermatologists came together to develop the targets, which encompass not only the treatment goals but also how long it should take to reach them. These are the first treatment targets for psoriasis in the United States.

The targets were developed through a lengthy process of research, discussion, and consensus-building among NPF Medical Board members, other leaders in the field of dermatology, and psoriasis patients. What resulted is a consensus on to what degree and how soon a patient and health care provider should strive to get clear skin.

Here are the specifics: The goal is to get psoriasis down to a body surface area (BSA) of 1% or less 3 months postinitiation of a new treatment. One percent BSA should then be maintained indefinitely with evaluations taking place every 6 months. In addition to the treatment target, the recommendations also offer what can be considered an “acceptable response” after 3 months—either BSA of 3% or less, or a 75% improvement in BSA.

Meeting the acceptable response could be a sign that the treatment is starting to work but may just need a little more time to reach the goal, according to Abby Van Voorhees, MD, chair of NPF’s Medical Board and a dermatologist at Eastern Virginia Medical School in Norfolk, VA.

“If a patient has absolutely no response after 3 months, that’s probably a clue that I’d better be thinking about some other things for the patient,” Dr Van Voorhees said. “On the other hand, if a patient has had a partial response, but maybe it’s not quite where I want it to be at that moment, then giving the medication a little longer might be needed. In that situation, I might give the medication the full 6 months to see if it will be effective. But at the end of 6 months of treatment, a patient should have achieved these goals,” she added.

No One-Size-Fits-All Treatment

That’s a big vote of confidence in the ability of psoriasis treatments to give everyone dramatically clearer skin. Before recent advances in therapeutic options,meeting this target may not have been possible.

“When I began my career, we had 2 or 3 treatment options total,” said Dr Van Voorhees. “There was a lot more tolerance for poor outcomes because the medications were not as effective and had more frequent potential side effects. The ability to achieve success was therefore so much more limited. But now we have so many more options that can work for somebody.”

Eric Fielding, 53, of Herndon, VA, was one of the patients involved in developing the targets. He has had psoriasis for about 25 years and has witnessed firsthand the advances in treatment that could make clear skin the expectation for all people with psoriasis.

Before the introduction of biologics, he said, topicals were often the go-to—but with limited success. “Now, I think that targets are more realistic. People can achieve results. But when I first started [treatment] back in the ’90s, it was more like, ‘You have eight spots. Let’s see if a different brand of cortisone will work,’” he recalled.

For Mr Fielding, it was an older treatment that finally did the trick for him. Two years ago, he started seeing a new dermatologist, who put him on narrowband phototherapy.

Phototherapy “has been a godsend,” he said. “I literally had something like 75 to 80 psoriasis spots all over my body a year-and-a-half ago. And now I’m down to 3 or 4.”

While the recommendations are very precise about the goals of treatment, they do not offer specifics on which treatments should be used to attain them. Many different treatment options could be used to meet the target goals, Dr Van Voorhees noted. “For example, if I had a patient who had persistent lesions on their legs, it could be that really what is required for that patient is to supplement the treatment that they are on with topical medicines, or potentially adding a second medication into the regimen. Or it could be switching therapies. It really very much depends on that individual,” she said.

The range of available therapies should help doctors and patients stay optimistic as they search for the right treatment.

“I try to explain to my patients that it may take a couple of tries before we find the regimen that works best for them or that they like the best. I try to set that stage right at the beginning,” Dr Van Voorhees explained.

“It can be very disheartening for a patient if they try something and have it not work or cause side effects that require stopping that treatment. Then they get discouraged.”

But understanding from the outset that they may need to try a few different options can lead to a much more positive experience.

“Then they come back in with the idea in their mind, ‘This one didn’t work. What’s next?’ As opposed to, ‘This one didn’t work. Now I have no hope,’” she said.

Story continues on page 2

How to Meet the Target

Alan Simmons, who was also involved in the development of the targets, has had psoriasis for more than 3 decades. For him, the targets can help doctors and patients find their way through what can be a frustrating process of finding the right treatment. “We can provide a road map to follow to ask the right questions at the right time,” he said.

His goals for treatment have changed over the years. “There was a time in my life when I had approximately 75% coverage. My target then was just to be able to wear shorts and T-shirts,” he said. “Now that I have less than 1% coverage, my target is to maintain my current treatment as long as possible.”

He and Mr Fielding both emphasize that it is important for doctors to understand the individual goals and concerns of each patient. Mr Fielding, for example, noted that other aspects of psoriasis—beyond the amount of the body that is covered—are important to people with the disease.

“There’s itching,there’s pain, there’s parts of the body,” he said. Having psoriasis on the genitals, or on the palms of the hands or soles of the feet, for instance, can have a big impact on someone’s quality of life, he explained.

“Basically, from a patient’s perspective, I think the most important thing is improvement,” Mr Fielding said.

Dr Armstrong hopes that these treatment targets will get patients and doctors talking about different therapeutic approaches.

“I think it’s really opening up the dialogue for all of the different options,” Dr Armstrong said.

Treatment goals can be part of an ongoing conversation between doctors and people with psoriasis, covering everything from what a particular person wants to get out of treatment, to why some therapies may be better than others.

“Psoriasis is a complex and unpredictable disease,” said Mr Simmons. He advises others living with psoriasis to find a doctor with whom they can openly discuss the challenges they may experience.

Mr Fielding has developed his own formula for achieving treatment goals.

“You have to have a balance of acceptance, confidence, and trust: Acceptance of your condition, confidence in yourself, and trust in your doctor,” he said. “If a patient embraces those qualities in themselves and their doctors, the path to improvement is there.”

Dr Leavitt is the former associate director of scientific communication at the National Psoriasis Foundation in Portland, OR.

April Armstrong, MD
Eric Fielding
Alan Simmons
Abby Van Voorhees, MD


1. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76(2) 290-298.

2. Treat 2 target. National Psoriasis Foundation website. Accessed June 13, 2017.

3. Orenstein B. Coming down the pipeline. National Psoriasis Foundation website. December 16, 2016. Accessed June 13, 2017.

4. Leavitt M. Why do we itch? National Psoriasis Foundation website. April 6, 2016. Accessed June 13, 2017.

Back to Top